Institutional
Omega Fund Management, LLC
CIK 0001637359
$163.1M
Reported AUM
10
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Omega Fund Management, LLC · Q1 2026
AI · grounded in 13F
Omega Fund Management, LLC closed its entire position in Upstream Bio Inc. UPB, reducing its exposure by $36.0M. The fund also trimmed its holdings in Alumis Inc. ALMS by 63.1% and Kestra Med Technologies Ltd KMTS by 25.6%. Conversely, the manager accumulated more shares of Bicara Therapeutics Inc. BCAX, increasing the position by 8.5%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics Inc. | $25.89 | -3.68% | 149.81% | 11.09% | $47.6M | 29.16% | — | HELD |
| 2 | NUVB | Nuvation Bio Inc. | $6.59 | -1.49% | 195.52% | -28.60% | $34.7M | 21.25% | — | HELD |
| 3 | BBOT | BridgeBio Oncology Therapeutics Inc. | $8.23 | -4.13% | -18.73% | -18.46% | $29.4M | 18.05% | — | HELD |
| 4 | KMTS | Kestra Med Technologies Ltd | $22.75 | -4.65% | 47.92% | -5.44% | $20.4M | 12.49% | — | HELD |
| 5 | BBNX | Beta Bionics Inc. | $15.17 | -3.99% | -7.50% | -27.66% | $13.2M | 8.08% | — | HELD |
| 6 | — | enGene Holdings Inc. | — | — | — | — | $6.0M | 3.66% | — | HELD |
| 7 | ALMS | Alumis Inc. | $26.38 | -2.40% | 543.95% | 116.22% | $5.3M | 3.26% | — | HELD |
| 8 | SANA | Sana Biotechnology, Inc. | $3.17 | -3.65% | -15.86% | -86.29% | $2.4M | 1.49% | — | HELD |
| 9 | IMA | ImageneBio, Inc. | $5.57 | -3.30% | -67.77% | -96.39% | $2.3M | 1.40% | — | HELD |
| 10 | REPL | Replimune Group | $5.41 | 1.12% | -28.82% | -82.97% | $1.9M | 1.17% | — | HELD |
Source: SEC EDGAR · accession 0001193125-26-225480. 13F discloses long positions only — shorts, foreign equities, and options are excluded.